会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • IMPLANTABLE MEDICAL DEVICE FOR TREATING CARDIAC MECHANICAL DYSFUNCTION BY ELECTRICAL STIMULATION
    • 医疗设备,植入机械心功能不全者通过电刺激治疗
    • EP1347704B1
    • 2007-12-19
    • EP01985621.0
    • 2001-12-26
    • MEDTRONIC, INC.
    • DENO, D., CurtisBENNETT, Tom, D.MULLIGAN, Lawrence, J.SHAW, Richard, J.IGEL, DavidHILL, Michael, R., S.
    • A61B5/00
    • A61N1/3627A61N1/36564
    • An implantable stimulator and monitor measures a group of heart failure parameters indicative of the state of heart failure employing EGM signals, measures of blood pressure including absolute pressure P, developed pressure (DP = systolic P diastolic P), and/or dP/dt, and measures of heart chamber volume (V) over one or more cardiac cycles. These parameters include: (1) relaxation or contraction time constant tau (t); (2) mechanical restitution (MR), ie., the mechanical response of a heart chamber to premature stimuli applied to the heart chamber; (3) recirculation fraction (RF), i.e., the rate of decay of PESP effects over a series of the heart cycles; and (4) end systolic elastance (EES), i.e., the ratios of end systolic blood pressure P to volume V. These heart failure parameters are determined periodically regardless of patient posture and activity level. The physician can determine whether a particular therapy is appropriate, prescribe the therapy for a period of time while again accumulating the stored patient data for a later review and assessment to determine whether the applied therapy is beneficial or not, thereby enabling periodic changes in therapy, if appropriate. Drug therapies and electrical stimulation therapies, including PESP stimulation, and pacing therapies including single chamber, dual chamber and multi-chamber (bi-atrial and/or bi-ventricular) pacing can be delivered. In patient's prone to malignant tachyarrhythmias, the assessment of heart failure state can be taken into account in setting parameters of detection or classification of tachyarrhythmias and the therapies that are delivered.
    • 3. 发明授权
    • SYSTEM FOR BI-VENTRICULAR FUSION PACING
    • 双室融合起搏系统
    • EP1446191B1
    • 2007-11-28
    • EP02763809.7
    • 2002-10-01
    • MEDTRONIC, INC.
    • HILL, Michael, R., S.
    • A61N1/368
    • A61N1/3627A61N1/3682A61N1/3684
    • Bi-ventricular cardiac pacing systems and systems for improving cardiac function for heart failure patients that pace and sense in right and left ventricles of the heart and particularly pace in one of the right and left ventricles after an AV delay timed from a preceding atrial event and after a spontaneous depolarization in the other of the right and left ventricles to achieve fusion pacing. An A-RVp delay and an A-LVp delay are each determined from an intrinsic sensed A-RVs delay and an intrinsic A-LVs delay. If the derived A-LVp delay becomes substantially equal to or shorter than the intrinsic A-RVs delay, then the A-RVp delay is decremented to be shorter than the A-LVp delay. Bi-ventricular pacing of the RV and LV is then established closely timed to the intrinsic RV and LV depolarizations.
    • 用于改善心脏衰竭患者的心脏功能的双心室心脏起搏系统和系统,其在心脏的右心室和左心室中起搏和感觉,并且特别是在从前一个心房事件开始的AV延迟之后的右心室和左心室之一中的起搏,以及 在另一个右心室和左心室自发去极化后实现融合起搏。 A-RVp延迟和A-LVp延迟各自根据内在感测的A-RV延迟和内在A-LV延迟来确定。 如果导出的A-LVp延迟基本上等于或短于固有A-RVs延迟,则A-RVp延迟减少为比A-LVp延迟短。 然后建立RV和LV的双心室起搏,密切定时到固有的RV和LV去极化。